Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19

 Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19

Pfizer and BioNTech Plan for Regulatory Review of its COVID-19 Vaccine in October 2020

Shots:

  • The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralizing titers following the second dose in an ongoing P-I/II study in Germany
  • The results divulge that BNT162b1 candidate induced strong CD4+ and CD8+ T-cell responses. BNT162b1 elicits RBD-specific, interferon-g+, IL-2+, CD8+ T cells in immunized participants indicating a strong potential for cell-mediated anti-viral activity
  • BNT162b1 induced broad neutralizing activity in pseudovirus neutralization assays across a panel of 16 SARS-CoV-2 RBD variants, including D614G strain. Data from German and US P-I/II studies will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress in global P-IIb/III safety and efficacy trial, expected to begin in Jul’20 end

Click here to read full press release/ article | Ref: Businesswire | Image: Barron

Related News: Pfizer and BioNTech Report Results of BNT162b1 mRNA-Based Vaccine in P-I/II Study Against COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post